^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MCLA-145

    i
    Other names: MCLA-145
    Associations

    News

    Trials
    Company:
    Merus
    Drug class:
    PD-L1 inhibitor, CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    over2years
    Phase I Dose Escalation Study of MCLA-145, a Bispecific Antibody Targeting CD137 and PD-L1 in Solid Tumors (ESMO-IO 2021)
    Legal entity responsible for the study The authors, Incyte Corporation, and Merus NV. Funding This study was funded by Incyte Corporation, Wilmington, DE, USA, and Merus NV, Utrecht, Netherlands.
    P1 data
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    MCLA-145